WallStreetZenWallStreetZen

NASDAQ: LABT
Lakewood Amedex Biotherapeutics Revenue

OverviewEarningsRevenue
DividendOwnership
Lakewood Amedex Biotherapeutics revenue was $0.00 for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LABT annual revenue was $0.0, with N/A growth year-over-year.

LABT revenue history

Current Revenue
$0.0
Current Earnings
-$3.8M
Current Profit Margin
0%

Be the first to know when LABT announces revenue.

LABT Revenue History By Year

LABT Yearly RevenueLABT RevenueLABT ChangeLABT Revenue Growth
2025-12-31$0.00N/AN/A
2024-12-31$0.00N/AN/A
2023-12-31$0.00N/AN/A

1 of 1

Lakewood Amedex Biotherapeutics Revenue FAQ

What was LABT's revenue last quarter?

Lakewood Amedex Biotherapeutics (NASDAQ: LABT) reported Q4 2025 revenue of $0.00 up N/A year over year. In the same quarter last year, Lakewood Amedex Biotherapeutics's revenue was $0.00.

What was Lakewood Amedex Biotherapeutics's revenue in 2025?

Lakewood Amedex Biotherapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.

How much does Lakewood Amedex Biotherapeutics make in a day?

Based on Lakewood Amedex Biotherapeutics annual revenue for the past two years, LABT makes an average of $0.00 per day.

What was Lakewood Amedex Biotherapeutics's annual revenue growth in the past year?

As of Q2 2026, Lakewood Amedex Biotherapeutics's revenue has grown null year over year. Lakewood Amedex Biotherapeutics's revenue in the past year totaled $0.00.

How much does Lakewood Amedex Biotherapeutics make in a year?

Lakewood Amedex Biotherapeutics's revenue by year for the past two years is:
  • Lakewood Amedex Biotherapeutics's revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.
  • Lakewood Amedex Biotherapeutics's annual revenue for Dec 31, 2024 was $0.00, a N/A decrease from 2023.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.